Clinical Trial Update: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis [Phase 3]

View source ↗

Summary

Seladelpar is being evaluated in a Phase 3 trial for primary biliary cholangitis with compensated cirrhosis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Seladelpar (seladelpar)

Snippet

Sponsor: Gilead Sciences | Conditions: Primary Biliary Cholangitis | Phase 3 | Status: RECRUITING